New Drug Approvals and Their Contract Manufacture – 2023 Edition
Access in-depth insight and stay ahead of the market
Explore actionable market insights from the following data in our ‘New Drug Approvals and Their Contract Manufacture’ report. This report is required reading for –
- CMO executives who must have a deep understanding of drug approvals and outsourcing to make strategic planning and investment decisions.
- Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
- Private equity investors who need a deeper understanding of the market to identify and value potential investment targets.
How is the ‘New Drug Approvals and Their Contract Manufacture’ report different from other reports in the market?
- The report provides 11 tables and 34 figures to illustrate major points and trends.
- Overview of NDA drug and vaccine approvals and the levels of outsourcing associated with NDA sub-segments.
- Detailed view of CDMO performance by number of drug and vaccine approvals
- An assessment of pharmaceutical companies’ propensity to outsource manufacture, by their market caps, based on GlobalData’s Contract Service Providers database.
- Outsourcing propensity for New Molecular Entities (NMEs), different dosage forms, and other drug attributes.
- Analysis of NME special product approvals such as those with Accelerated Approval, Orphan, Breakthrough, or Fast Track designations and assessment of outsourcing.
We recommend this valuable source of information to anyone involved in:
- Pharmaceutical Industry (Big Pharma, Small Biotech, Start-Ups, etc.),
- Pharmaceutical Industry Suppliers (e.g., Consulting Companies, CMOs, CDMOs, CROs, Technology Vendors)
- Professional Services (e.g., Investment Companies, Investment Banks, etc.)
- Clinical Research Organisations (CROs)
- Government/Financial Institutions (Investors in Pharma/Biotech, Pricing Consultancies)
- Professional Services – Investment Banks, PE/VC firms
- M&A/Investment, Management Consultants, and Consulting Firms
To get a snapshot of the new drug approvals and their contract manufacture report, download a free report sample
New Drug Approvals and their Contract Manufacture Report Overview
In 2022, the FDA approved 109 new drug applications (NDAs) and biologics license applications (BLAs). The overall number of approvals is eight lower when compared to 2021. Both small molecule and biologic new molecular entity (NME) approvals declined substantially, causing overall NDA approvals to drop, which meant fewer commercial-scale production contracts for the most innovative products compared to other recent years. Small cap companies’ (market cap $300M–2B) and private companies’ NDA approvals were relatively high in 2022, with 15 and 42 FDA approvals, respectively. In recent years, COVID-19 vaccine drives have allowed economies and societies to safely reopen during the pandemic. However, new challenges such as rising inflation will bring uncertainty to the ongoing global recovery. The pharma industry faces increasing cost pressures, shrinking consumer spending power, staff shortages, and geopolitical tensions.
The new drug approvals and their contract manufacture report is the 13th edition of a long-running analysis of the CMO industry, using the FDA’s NDA approvals as the primary indicator of performance. New Drug Approvals and Their Contract Manufacture (formerly called “CMO Scorecard”) is critical for benchmarking the performance of the contract manufacturing organization (CMO) industry and the relative performance of major CMOs. This year’s edition includes a discussion of Emergency Use Approvals for COVID-19 and how inflation has impacted pharma manufacturers.
For more insights on the new drug approvals and their contract manufacture forecasts, download a free sample report
New Drug Approvals and their Contract Manufacture – Key Trends
The main trends that affected FDA drug approvals and their manufacturing in 2022 are classified into three categories: approval types, increased outsourcing, and changing business environment.
Approval types: Record cell/gene therapy approvals continue 2021’s strong performance, huge drop in FDA approvals for NMEs, and biologic NME approvals outnumbered small molecules in 2022 are some of the top approval type trends in new drug approvals and their contract manufacture study.
Increased outsourcing: Domination of dose outsourcing by a few key CMOs, higher biologic NME outsourcing than for small molecule equivalents, and more reliance on nano and micro cap sponsors on CMOs are some of the increased outsourcing trends boosting new drug approvals and their contract manufacture.
Changing business environment: The impact of inflation on pharma manufacturing and shifts in market demand are likely to impact the new drug approvals and their contract manufacture. In addition, although many of the vaccines will still generate blockbuster revenues, sales will decrease, as will the volumes of production. COVID-19 vaccines and treatments will still represent lucrative contracts for CMOs, but with production volumes dwindling and manufacturing relationships becoming well-established, are less profitable than in earlier stages of the pandemic.
For more insights on the new drug approvals and their contract manufacture trends, download a free sample report
New Drug Approvals and their Contract Manufacture Industry Analysis
New Drug Approvals and Their Contract Manufacture – 2023 Edition analyzes the performance of the pharmaceutical CMO industry, using NDA and BLA approvals by the FDA and new active substance (NAS) approvals by the EMA’s central pathway as the primary indicators of performance.
The new drug approvals and their contract manufacture report also covers –
- FDA NDA approvals overview
- US vs. EU approval performance
- FDA EUAs in 2022 for COVID-19
- FDA: outsourced dose manufacture
- Special product categories
- Outsourcing by company market cap
- CMO performance
- Outsourced API approvals
- ANDA approvals
- What it means
For more new drug approvals and their contract manufacture industry analysis, download free sample
New Drug Approvals and their Contract Manufacture – Value Chain Insights
The contract manufacturing industry’s value chain is simplified into three main segments, beginning with API, dose form manufacturing, and packaging. API is the starting point and can have big implications on which dosage forms or packaging are used later in the process. For instance, if there were a greater number of contract service agreements being made for biologic API manufacture, this would have major implications for injectable dose form manufacturing and packaging.
New Drug Approvals and their Contract Manufacture Value Chain Insights
For additional value chain insights in the new drug approvals and contract manufacture report, download a free sample
New Drug Approvals and their Contract Manufacture – Competitive Landscape
The key CMOs and pharma companies making a mark in dose manufacturing are CMOs Almac, Catalent, PCI Pharma Services, Thermo Fisher Scientific (owner of Patheon), and Vetter. Some other companies with Center for Biologics Evaluation and Research approvals are Ferring Pharmaceuticals Inc, CSL Behring LLC, bluebird bio Inc, GlaxoSmithKline LLC, Janssen Biotech Inc, and Moderna Inc.
For more insights on the sponsors and companies in new drug approvals and their contract manufacture report, download a free sample report
New Drug Approvals and their Contract Manufacture Outlook
|Key Trends||Approval Types, Increased Outsourcing, and Changing Business Environment|
|Key Value Chain Components||API, Dose formation, and Packaging|
|Key Companies||CMOs Almac, Catalent, PCI Pharma Services, Thermo Fisher Scientific (owner of Patheon), and Vetter|
Key PlayersAbbVie Inc
ACS Dobfar SpA
Aenova Holding GmbH
Afton Scientific Corp
AGC Biologics Inc
Ajinomoto Bio-Pharma Services
Akorn Operating Company LLC
Allergopharma GmbH & Co KG
Almac Group Ltd
Alpex Pharma SA
Altasciences Co Inc
ASM Aerosol-Service AG
AtomVie Global Radiopharma Inc
Aurobindo Pharma Ltd
Avara Pharmaceutical Services Inc
Bausch & Lomb Pharmaceuticals Inc
Baxter Biopharma Solutions
Berkshire Sterile Manufacturing LLC
Boehringer Ingelheim Biopharmaceuticals GmbH
Boehringer Ingelheim RCV GmbH & Co KG
Bora Pharmaceuticals Co Ltd
Bristol Myers Squibb Co
BSP Pharmaceuticals SpA
Bushu Pharmaceuticals Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Contract Pharmaceuticals Ltd
Corden Pharma International GmbH
Curia Global Inc
Dexcel PT Israel Ltd
DPT Laboratories Ltd
Eisai Co Ltd
EMD Serono Inc
Emergent BioSolutions Inc
Eurofins Scientific SE
Excella GmbH & Co KG
Exela Pharma Sciences LLC
Ferndale Pharma Group Inc
Fidia farmaceutici SpA
Fresenius Kabi AG
Fritz Keller Holding AG
Fuji Yakuhin Co Ltd
FUJIFILM Diosynth Biotechnologies USA Inc
Gensenta Ilac Sanayi ve Ticaret AS
Gilead Sciences Inc
Gland Pharma Ltd
Groupe Parima Inc
Hikma Pharmaceuticals Plc
Holopack Verpackungstechnik GmbH
Hovione FarmaCiencia SA
IDT Biologika GmbH
Institutt for Energiteknikk
Iwaki Seiyaku Sakura Factory Co Ltd
James Alexander Corp
Jubilant HollisterStier LLC
Juzen Chemical Corp
KP Pharmaceutical Technology Inc
Kyowa Hakko Bio Co Ltd
Laboratorios Farmaceuticos Rovi SA
LGM Pharma LLC
Lifecore Biomedical LLC
Lonza Group Ltd
LTS Lohmann Therapie-Systeme AG
Lyne Laboratories Inc
Lyophilization Services of New England Inc
Mawdsley-Brooks & Co Ltd
MIAS Pharma Ltd
Mibe GmbH Arzneimittel
Minaris Regenerative Medicine LLC
National Resilience Inc
Neolpharma SA De CV
Nephron Pharmaceuticals Corp
NextPharma Technologies Holding Ltd
Nova Laboratories Ltd
Novast Holdings Ltd
NUVISAN Pharma Holding GmbH
Oncotec Pharma Produktion GmbH
Organon & Co
PARI Pharma GmbH
PCI Pharma Services
Pharmaceutical Manufacturing Research Services Inc
Pharmaceutics International Inc
Pharmathen Global BV
Piramal Pharma Solutions Inc
Polymun Scientific Immunbiologische Forschung GmbH
PYRAMID Laboratories Inc
Qilu Pharmaceutical Co Ltd
QPS Holdings LLC
Quay Pharmaceuticals Ltd
Quotient Sciences Ltd
Rechon Life Science AB
Renaissance Lakewood LLC
Rentschler Biopharma SE
Rottendorf Pharma GmbH
Samsung Biologics Co Ltd
Sandoz International GmbH
Sawai Pharmaceutical Co Ltd
Sever Pharma Solutions AB
Sharp Packaging Services
Sichuan Huiyu Pharmaceutical Co Ltd
Siegfried Holding AG
Sirton Pharmaceuticals SpA
Societal CDMO Inc
Stada Arzneimittel AG
Takeda Pharmaceutical Co Ltd
Teikoku Seiyaku Co Ltd
The Biovac Institute
The Ritedose Corp
Thermo Fisher Scientific Inc
TOYO Pharmaceutical Co Ltd
Toyobo Co Ltd
Tulex Pharmaceuticals Inc
Unither Pharmaceuticals SAS
UPM Pharmaceuticals Inc
Vetter Pharma-Fertigung GmbH & Co KG
Woodstock Sterile Solutions
WuXi Biologics Cayman Inc
Xellia Pharmaceuticals ApS
Zydus Lifesciences Ltd
Table of Contents
- 1 Executive Summary
- 2 Players
- 3 Technology Briefing
- 3.1 Innovative drug approvals
- 3.2 Dose outsourcing of drug approvals
- 4 Trends
- 5 Industry Analysis
- 5.1 Introduction
- 5.2 FDA NDA approvals overview
- 5.2.1 More biologic NME approvals than small molecule equivalents
- 5.2.2 Cell and gene therapies
- 5.2.3 First-in-class
- 5.2.4 First-time approvals
- 5.2.5 Rejected drugs
- 5.2.6 Predicted approvals for 2023
- 5.2.7 Sponsor trends
- 5.3 US vs. EU approval performance
- 5.4 FDA EUAs in 2022 for COVID-19
- 5.5 FDA: outsourced dose manufacture
- 5.5.1 Dosage form outsourcing
- 5.6 Special product categories
- 5.6.1 Accelerated approvals
- 5.6.2 Orphan drug designation
- 5.6.3 Fast track designation
- 5.6.4 Breakthrough therapy designation
- 5.6.5 Containment
- 5.6.6 Solubility enhancement
- 5.7 Outsourcing by company market cap
- 5.8 CMO performance
- 5.8.1 Dosage form
- 5.9 Outsourced API approvals
- 5.10 ANDA approvals
- 5.11 What it means
- 5.11.1 FDA approvals decline with a large decrease of NMEs approved
- 5.11.2 COVID-19 vaccine demand waning but there are still lucrative contracts
- 5.11.3 A few large CMOs gain majority of dose contracts
- 5.11.4 High inflation and other business conditions
- 5.11.5 Record high number of ATMP approvals in 2022
- 6 Value Chain
- 7 Companies
- 8 Appendix
- 8.1 Methodology
- 8.2 Bibliography
- 8.3 Primary research – key opinion leaders
- 8.4 Further reading
- 9 About the Authors
Table 1: Drug approval trends, 2022
Table 2: FDA and EMA drug filings rejected or withdrawn in 2022
Table 3: Predicted drug events in 2023
Table 4: Dose outsourcing of therapies and vaccines granted FDA emergency use approval for COVID-19 in 2020–22
Table 5: Outsourced NDA approvals by dosage form
Table 6: Dose outsourcing relationships by sponsor market cap and FDA approval type, 2017–22
Table 7: CMOs with API contracts for NMEs approved in 2022
Table 8: Companies with 2022 Center for Biologics Evaluation and Research (CBER) approvals
Table 9: 2022 outsourced dose approvals
Table 10: CMOs receiving dose contracts for FDA approvals in 2013–22
Table 11: 2022 outsourced API approvals
Table 12: CMOs receiving dose contracts for FDA approvals in 2022
Table 13: Further reading
Figure 1: Leading players for US new drug approvals and their manufacturing, 2022
Figure 2: Top drug approval trends, 2022
Figure 3: FDA NDA and BLA approvals, 2013–22
Figure 4: FDA biologic NME approvals, 2013–22
Figure 5: FDA NDA approvals by sponsor type, 2013–22
Figure 6: EMA approvals, 2013–22
Figure 7: FDA EUAs for COVID-19 products, 2020–22
Figure 8: Share of FDA NDA approvals outsourced, 2013–22
Figure 9: NDA approvals outsourced, 2013–22
Figure 10: Dose outsourcing of small molecule and biologic NMEs, 2013–22
Figure 11: Dose outsourcing of FDA NME approvals by sponsor market cap
Figure 12: Dose outsourcing of non-NME NDA approvals by sponsor market cap
Figure 13: Dose outsourcing of accelerated approval NMEs, 2013–22
Figure 14: Dose outsourcing of FDA orphan NMEs, 2013–22
Figure 15: Dose outsourcing of FDA fast track NMEs, 2013–22
Figure 16: Dose outsourcing of breakthrough therapy designation NMEs, 2013–22
Figure 17: NME approvals requiring special handling, 2013–22
Figure 18: FDA approvals and outsourcing of NMEs utilizing solubility enhancement, 2013–22
Figure 19: Small, micro, and nano cap sponsors’ dose outsourcing propensity for NMEs, 2013–22
Figure 20: Small, micro, and nano cap sponsors’ dose outsourcing propensity for non-NMEs, 2013–22
Figure 21: Mid cap sponsors’ dose outsourcing propensity, 2013–22
Figure 22: Large cap dose outsourcing propensity, 2013–22
Figure 23: Mega cap dose outsourcing propensity, 2013–22
Figure 24: Private company dose outsourcing propensity, 2013–22
Figure 25: Breakdown in composition of dose-outsourced NMEs, by sponsor market cap, 2013–22
Figure 26: Dose-outsourced non-NME NDAs, by sponsor market cap, 2013–22
Figure 27: CMO market share of parenteral NME approvals, 2013–22
Figure 28: CMO market share of parenteral non-NME NDA and biosimilar approvals, 2013–22
Figure 29: CMO market share of solid dose NME approvals, 2013–22
Figure 30: CMO market share of solid dose non-NME NDA approvals, 2013–22
Figure 31: API outsourcing of small molecule and biologic NMEs, 2013–22
Figure 32: ANDA approvals by dosage form, 2013–22
Figure 33: ANDA approvals by route of administration, 2013–22
Figure 34: The contract manufacturing value chain
Frequently asked questions
How many new drug applications (NDAs) and biologics license applications (BLAs) were approved by FDA in 2022?
In 2022, the FDA approved 109 new drug applications (NDAs) and biologics license applications (BLAs).
What are the key trends in new drug approvals and their contract manufacture industry?
The key trends in new drug approvals and their contract manufacture are approval types, increased outsourcing, and changing business environment.
Which are the key value chain components in new drug approvals and their contract manufacture industry?
The key value chain components in the new drug approvals and their contract manufacture industry are API, dose formation, and packaging.
Who are the key players in new drug approvals and their contract manufacture sector?
CMOs Almac, Catalent, PCI Pharma Services, Thermo Fisher Scientific (owner of Patheon), and Vetter are some of the leading players in new drug approvals and their contract manufacture sector.
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Business Intelligence & Marketing Manager, SAL Heavy Lift
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
Market Analyst & Management, Liebherr-Werk
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Head of Key Accounts, Saab AB
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Marketing Intelligence Manager, Portugal Foods
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Head of Customer Insight and Research, Standard Chartered
Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.
I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.
I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.
Head of Consumer Sensory Insights, Givaudan
“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.
Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”
Senior Account Manager, TSYS
GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.
I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.
One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.